These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 37338204)

  • 21. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
    Watts C; Burton S; Freeman B
    Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA.
    Henderson KC; Van Do V; Wang Y; Duan Z; Popova L; Spears CA; Weaver SR; Ashley DL; Barker DC; Huang J
    Tob Control; 2023 Aug; 32(e2):e260-e264. PubMed ID: 35918133
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Social Media Discussions on the FDA's Modified Risk Tobacco Product Authorization of IQOS.
    Jun J; Zhang N; Zain A; Mohammadi E
    Subst Use Misuse; 2022; 57(3):472-480. PubMed ID: 34986075
    [No Abstract]   [Full Text] [Related]  

  • 24. Informing iQOS Regulations in the United States: A Synthesis of What We Know.
    Berg CJ; Bar-Zeev Y; Levine H
    Sage Open; 2020; 10(1):. PubMed ID: 32719733
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Heated tobacco products likely appeal to adolescents and young adults.
    McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Revolution or redux? Assessing IQOS through a precursor product.
    Elias J; Dutra LM; St Helen G; Ling PM
    Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
    Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
    Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Corporate communication of the relative health risks of IQOS through a webchat service.
    Braznell S; Branston JR; Gilmore AB
    Tob Control; 2023 Aug; 32(e2):e205-e211. PubMed ID: 35241501
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Landscape of Cigar Marketing in Print Magazines from 2018-2021: Content, Expenditures, Volume, Placement and Reach.
    Ganz O; Wackowski OA; Gratale S; Chen-Sankey J; Safi Z; Delnevo CD
    Int J Environ Res Public Health; 2022 Dec; 19(23):. PubMed ID: 36498246
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.
    Kim M; Watkins SL; Koester KA; Mock J; Kim HC; Olson S; Harvanko AM; Ling PM
    Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33153143
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlates of Perceptions, Use, and Intention to Use Heated Tobacco Products Among US Young Adults in 2020.
    Duan Z; Wysota CN; Romm KF; Levine H; Bar-Zeev Y; Choi K; Berg CJ
    Nicotine Tob Res; 2022 Nov; 24(12):1968-1977. PubMed ID: 35901840
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of Modified Risk Tobacco Product Claims on Consumer Responses.
    Seidenberg AB; Boynton MH; Brewer NT; Lazard AJ; Sheeran P; Ribisl KM
    Nicotine Tob Res; 2024 Mar; 26(4):435-443. PubMed ID: 37791605
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anticipating IQOS market expansion in the United States.
    Abroms L; Levine H; Romm K; Wysota C; Broniatowski D; Bar-Zeev Y; Berg C
    Tob Prev Cessat; 2022; 8():04. PubMed ID: 35174298
    [TBL] [Abstract][Full Text] [Related]  

  • 34. IQOS labelling will mislead consumers.
    McKelvey K; Popova L; Kim M; Lempert LK; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
    Tob Control; 2018 Nov; 27(Suppl 1):s48-s54. PubMed ID: 30158208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Categorizing IQOS-Related Twitter Discussions.
    Barker JO; Vassey J; Chen-Sankey JC; Allem JP; Cruz TB; Unger JB
    Int J Environ Res Public Health; 2021 Apr; 18(9):. PubMed ID: 33946546
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Heated tobacco product marketing: a mixed-methods study examining exposure and perceptions among US and Israeli adults.
    Cui Y; Bar-Zeev Y; Levine H; LoParco CR; Duan Z; Wang Y; Abroms LC; Khayat A; Berg CJ
    Health Educ Res; 2024 Jul; 39(4):375-397. PubMed ID: 38739472
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Industry marketing of tobacco products on social media: case study of Philip Morris International's IQOS.
    Abroms LC; Wysota CN; Tosakoon S; Khayat A; Duan Z; Bar-Zeev Y; Berg CJ; Levine H
    Tob Control; 2024 Jun; 33(4):518-524. PubMed ID: 36927516
    [TBL] [Abstract][Full Text] [Related]  

  • 38. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
    McKelvey K; Baiocchi M; Halpern-Felsher B
    Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of IQOS Marketing Strategies at Points-of-Sale in Israel at a Time of Regulatory Transition.
    Bar-Zeev Y; Berg CJ; Abroms LC; Rodnay M; Elbaz D; Khayat A; Levine H
    Nicotine Tob Res; 2022 Jan; 24(1):100-108. PubMed ID: 34216461
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IQOS and cigarette advertising across regulatory periods and population groups in Israel: a longitudinal analysis.
    Khayat A; Levine H; Berg CJ; Shauly-Aharonov M; Manor O; Abroms L; Romm KF; Wysota CN; Bar-Zeev Y
    Tob Control; 2024 Mar; 33(e1):e3-e10. PubMed ID: 36368887
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.